Vaccines: past, present and future

The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines.

[1]  R. Rabinovich,et al.  Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Plotkin,et al.  Six Revolutions in Vaccinology , 2005, The Pediatric infectious disease journal.

[3]  Diane E. Sutter,et al.  Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery , 2002, Nature Medicine.

[4]  R. Rappuoli,et al.  Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. , 2004, Journal of biotechnology.

[5]  Lihan K. Yan,et al.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.

[6]  J. Wood,et al.  From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza , 2004, Nature Reviews Microbiology.

[7]  B. Graham,et al.  Modified vaccinia Ankara: potential as an alternative smallpox vaccine. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  G. Glenn,et al.  Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin , 2003, Expert review of vaccines.

[9]  J. Rayner,et al.  Alphavirus vectors and vaccination , 2002, Reviews in medical virology.

[10]  S. Plotkin.  Immunologic correlates of protection induced by vaccination , 2001, The Pediatric infectious disease journal.

[11]  Max Theiler,et al.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION , 1937, The Journal of experimental medicine.

[12]  C. Alving,et al.  Transcutaneous immunization: T cell responses and boosting of existing immunity. , 2001, Vaccine.

[13]  E. Fikrig,et al.  Protection of mice against the Lyme disease agent by immunizing with recombinant OspA , 1990, Science.

[14]  A. Fattom,et al.  Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. , 2004, Vaccine.

[15]  G. Nabel,et al.  Generation of Synthetic Severe Acute Respiratory Syndrome Coronavirus Pseudoparticles: Implications for Assembly and Vaccine Production , 2004, Journal of Virology.

[16]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[17]  L. Stanberry.  Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. , 2004, Herpes : the journal of the IHMF.

[18]  H. Robinson,et al.  Nucleic acid vaccines: an overview. , 1997, Vaccine.

[19]  M. Levin,et al.  Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. , 2003, The Journal of infectious diseases.

[20]  K. Edwards,et al.  Combination Vaccines , 1999, Humana Press.

[21]  Diego G. Silva,et al.  Vaccine Therapies for the Prevention of Type 1 Diabetes Mellitus , 2003, Paediatric drugs.

[22]  B. Reid.  A nucleic Acid. , 1979, Science.

[23]  R. Karron,et al.  Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  O. Singh,et al.  Regain of Fertility and Normality of Progeny Born During Below Protective Threshold Antibody Titers in Women Immunized With the HSD‐hCG Vaccine , 1998, American journal of reproductive immunology.

[25]  L. Pirofski,et al.  Vaccines for the prevention of diseases caused by potential bioweapons. , 2004, Clinical immunology.

[26]  Spaete Rr.  A recombinant subunit vaccine approach to HCMV vaccine development. , 1991 .

[27]  D. Bernstein,et al.  Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. , 1998, Vaccine.

[28]  D. Greenberg,et al.  New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. Matriano,et al.  Macroflux® Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous Immunization , 2004, Pharmaceutical Research.

[30]  A. Moore,et al.  Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria , 2004, Immunological reviews.

[31]  P. Lambert,et al.  Can successful vaccines teach us how to induce efficient protective immune responses? , 2005, Nature Medicine.

[32]  L. Nencioni,et al.  Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.

[33]  W. Strober,et al.  Mucosal HIV vaccines: where are we now? , 2004, Current HIV research.

[34]  R. Hohlfeld,et al.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[36]  J. Schiller,et al.  Delivering on the promise: HPV vaccines and cervical cancer , 2004, Nature Reviews Microbiology.

[37]  A. García-Sastre,et al.  Influenza vaccines: present and future. , 2002, The Journal of clinical investigation.

[38]  M. Horwitz,et al.  A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis , 2003, Infection and Immunity.

[39]  D. Klinman.  Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.

[40]  P. Moore,et al.  Corrected prevalence of Kaposi's sarcoma (KS)-associated herpesvirus infection prior to onset of KS. , 1997, AIDS.

[41]  D. O'Kane,et al.  Gene expression microarrays: a 21st century tool for directed vaccine design. , 2001, Vaccine.

[42]  W. Szmuness,et al.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report , 1981, Hepatology.

[43]  R. Spaete.  A recombinant subunit vaccine approach to HCMV vaccine development. , 1991, Transplantation proceedings.

[44]  P. S. St George-Hyslop,et al.  Immunotherapy for Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  L. Stamatatos,et al.  Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. , 2004, Virology.

[46]  Brigitte Autran,et al.  Host Defenses against Viral Infection , 2002 .

[47]  P. Vandepapelière.  Therapeutic vaccination against chronic viral infections. , 2002, The Lancet. Infectious diseases.

[48]  F. Guirakhoo,et al.  Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates , 2004, Journal of Virology.

[49]  F. Robbins,et al.  Cultivation of Poliomyelitis Virus in Cultures of Human Foreskin and Embryonic Tissues.∗ , 1949, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[50]  Jonathan J. Lewis,et al.  Therapeutic cancer vaccines: Using unique antigens , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. O’Garra,et al.  Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.

[52]  C. Leonardi,et al.  Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  S. Wesselingh,et al.  Successful Boosting of a DNA Measles Immunization with an Oral Plant-Derived Measles Virus Vaccine , 2002, Journal of Virology.

[54]  D. Kasper,et al.  Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. , 2004, The Journal of infectious diseases.

[55]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.

[56]  E. D. Kilbourne,et al.  Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in ovo adaptation of early passage Asian strain isolates by combination with PR8. , 1960 .

[57]  A. Kapikian,et al.  Rotavirus vaccines. , 1992, Biotechnology.

[58]  P. Piedra,et al.  Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. , 2003, Vaccine.

[59]  P. Earl,et al.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.

[60]  Tokiko Watanabe,et al.  Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. L. Valdespino-Gómez,et al.  A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. , 2002, Vaccine.

[62]  Joyce E. Chaplin,et al.  Pox Americana: The Great Smallpox Epidemic of 1775-82 , 2001 .

[63]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[64]  M. Plante,et al.  A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. , 2003, Vaccine.

[65]  K. Subbarao.  Influenza vaccines: present and future. , 1999, Advances in virus research.

[66]  H. Grönlund,et al.  Vaccination with genetically engineered allergens prevents progression of allergic disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Foidart,et al.  Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein–based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia , 2004, Cancer Immunology, Immunotherapy.

[68]  J. Excler,et al.  The prime-boost concept applied to HIV preventive vaccines. , 1997, AIDS.

[69]  J. Bond,et al.  Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model , 2000, Psychopharmacology.

[70]  Y. Maa,et al.  Epidermal powder immunization of mice and monkeys with an influenza vaccine. , 2003, Vaccine.

[71]  A. Perelson,et al.  Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. , 2002, The Journal of infectious diseases.

[72]  M. Hilleman,et al.  Human hepatitis B vaccine from recombinant yeast , 1984, Nature.

[73]  G. Matyas,et al.  Needle-Free Skin Patch Vaccination Method for Anthrax , 2004, Infection and Immunity.

[74]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[75]  A. Nesburn,et al.  Lipopeptide vaccines--yesterday, today, and tomorrow. , 2002, The Lancet. Infectious diseases.

[76]  P. Moingeon,et al.  Towards the rational design of Th1 adjuvants. , 2001, Vaccine.

[77]  P. Mettens,et al.  Life-style vaccines. , 2002, British medical bulletin.

[78]  J. Nelson,et al.  The Final Report , 2005 .